Headache

FDA Approves Repatha® (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia

Saturday, September 25, 2021 - 1:09am

The approval is based on the HAUSER-RCT Phase 3b study evaluating the safety and efficacy of Repatha in pediatric patients, 10 - 17 years of age, with HeFH.

Key Points: 
  • The approval is based on the HAUSER-RCT Phase 3b study evaluating the safety and efficacy of Repatha in pediatric patients, 10 - 17 years of age, with HeFH.
  • The FDA also approved Repatha as an adjunct to other LDL-C lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH) for younger pediatric patients.
  • Repatha was already approved for treatment in HoFHpatients aged 13 and older and is now available as a treatment for patients aged 10 and older.
  • Randomization was stratified by LDL-C (

Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency

Saturday, September 25, 2021 - 1:04am

The use of the liquid form of this product may fail to treat severe low blood sugar due to loss of potency.

Key Points: 
  • The use of the liquid form of this product may fail to treat severe low blood sugar due to loss of potency.
  • Glucagon Emergency Kit is used as an anti-hypoglycemic agent and a gastrointestinal motility inhibitor indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus.
  • The affected Glucagon Emergency Kit lot is D239382D and the expiration date is April 2022 (label expiry date: 04 2022).
  • Wholesalers and Distributors with an existing inventory of Glucagon Emergency Kit lot D239382D should cease distribution and quarantine the product immediately.

National Headache Foundation Launches Primary Care Migraine Program

Friday, September 24, 2021 - 6:27pm

Chicago, IL, Sept. 24, 2021 (GLOBE NEWSWIRE) -- The National Headache Foundation (NHF) launched Primary Care Migraine, a new educational training program available at no cost to health practitioners.

Key Points: 
  • Chicago, IL, Sept. 24, 2021 (GLOBE NEWSWIRE) -- The National Headache Foundation (NHF) launched Primary Care Migraine, a new educational training program available at no cost to health practitioners.
  • The program was announced by Tom Dabertin, Executive Director and Chief Executive Officer of the National Headache Foundation.
  • Dabertin said participationincludes two hours of free CME and a complimentary membership to the National Headache Foundation.
  • For more details on the NHFs Primary Care Migraine program, please visit https://www.pcmigraine.com/
    The National Headache Foundation (NHF) is the leading educational and informational resource for individuals with headache, their families, physicians, allied health care professionals, and health policy decision makers.

Box Pure Air's Highly Effective Plug And Play Solution Removes Air Quality Pollutants

Friday, September 24, 2021 - 3:15pm

As discussed in the 2010 study by National Institute for Respiratory Health of Mexico, "a substantial amount of respiratory illness stems from unclean indoor air."

Key Points: 
  • As discussed in the 2010 study by National Institute for Respiratory Health of Mexico, "a substantial amount of respiratory illness stems from unclean indoor air."
  • Microscopic particles in the air can cause minor pains (literally) like headaches, nausea and dizziness to full blown respiratory illness like asthma.
  • Besides causing reportable illness, poor indoor air quality has been proven to lead to lower test scores and decreased focus in students.
  • Box Pure Air has a highly effective plug and play solution to these problems for any size room within your home, school, or office.

Athletico Physical Therapy Opens in Greensburg

Friday, September 24, 2021 - 1:00pm

GREENSBURG, Ind., Sept. 24, 2021 /PRNewswire/ -- Athletico Physical Therapy has opened a new location in Greensburg, located in Greensburg Commons in front of Walmart Supercenter and next to Starbucks.This location offers convenient hours with early morning, late evening and Saturday appointment options, and does not require a referral or prescription to start treatment.

Key Points: 
  • GREENSBURG, Ind., Sept. 24, 2021 /PRNewswire/ -- Athletico Physical Therapy has opened a new location in Greensburg, located in Greensburg Commons in front of Walmart Supercenter and next to Starbucks.This location offers convenient hours with early morning, late evening and Saturday appointment options, and does not require a referral or prescription to start treatment.
  • In addition to in-clinic treatment at the Greensburg clinic, Athletico is also offering telehealth virtual treatment options where patients can connect with a physical therapist through a secure online video chat.
  • "As the clinic manager for Athletico, I look forward to bringing physical therapy services to Greensburg and making lifelong connections in the area," said Cody Bond, PT, DPT and Clinic Manager of Athletico Greensburg.
  • Services available at Athletico Greensburg include:
    Physical therapy Our physical therapists treat you to reduce pain, improve or restore mobility, and to help you remain at your optimal health without further risk of injury.

Advisory - Health Canada suspends licence and requested a recall for PURE75 gel hand sanitizer due to potential serious health risks

Thursday, September 23, 2021 - 10:00pm

Health Canada has suspended the product licence for PURE75 gel hand sanitizer (NPN 80098346) due to health risks.

Key Points: 
  • Health Canada has suspended the product licence for PURE75 gel hand sanitizer (NPN 80098346) due to health risks.
  • In addition, Health Canada suspended Haywick Industries' site licence, which means it cannot manufacture, package, label, or import hand sanitizer products.
  • Report any health product side effects or complaints to Health Canada.
  • Health Canada also maintains a list of recalled hand sanitizers and encourages Canadians to check it for updates.

WA Poison Center advises caution following harmful algae alerts

Thursday, September 23, 2021 - 6:23pm

SEATTLE, Sept. 23, 2021 /PRNewswire/ --After reports of harmful algae blooms in local bodies of water, the Washington Poison Center is advising the public to be careful when recreating in and around lakes and rivers.

Key Points: 
  • SEATTLE, Sept. 23, 2021 /PRNewswire/ --After reports of harmful algae blooms in local bodies of water, the Washington Poison Center is advising the public to be careful when recreating in and around lakes and rivers.
  • Freshwater algae blooms are caused by "blue-green algae," which are a type of bacteria called "cyanobacteria."
  • Blue-green algae can become a problem, however, when certain toxin-producing strains rapidly reproduce (or "bloom")a common occurrence in the warmer, sunny months of summer and fall.
  • If you think you have come into contact with blue-green algae, shower (with soap) and call the Poison Center at 1-800-222-1222.

DGAP-News: Abivax presents first-half 2021 financial results and operations update

Thursday, September 23, 2021 - 5:23pm

2021 Research Tax Credit revenue amounts to EUR 1.6M as of June 30, 2021.

Key Points: 
  • 2021 Research Tax Credit revenue amounts to EUR 1.6M as of June 30, 2021.
  • Cash at the end of June 2021 was EUR 4.3M, compared to EUR 29.3M at the end of 2020, before taking into account the EUR 85M financing realized in July 2021.
  • In March 2021, Abivax announced it would be stopping the phase 2b/3 Covid-19 study (miR-AGE trial - ABX464-401) due to lack of efficacy.
  • Abivax would like to thank him for his contribution and wishes him all the best in his future endeavors.

TFF Pharmaceuticals Announces Promising Topline Results from Phase 1 Clinical Trial of Inhaled Tacrolimus Powder and Progression Toward Phase 2 in Lung Transplantation

Thursday, September 23, 2021 - 1:00pm

This flexible dosing approach will also be reflected in the design for our upcoming Phase 2 study in lung transplant recipients.

Key Points: 
  • This flexible dosing approach will also be reflected in the design for our upcoming Phase 2 study in lung transplant recipients.
  • The eight subjects in each cohort included six subjects randomized to receive tacrolimus and two randomized to receive placebo.
  • TFF Pharmaceuticals expects to take critical steps toward beginning its Phase 2 clinical study of Inhaled Tacrolimus Powder by the end of 2021.
  • It is exciting for our patients and for us as clinicians to have a potential new option with Inhaled Tacrolimus Powder.

Numinus Completes Acquisition of Neurology Centre of Toronto

Thursday, September 23, 2021 - 2:00pm

Founded in 2017 by Dr. Evan Lewis (MD), NCT will operate as the "Neurology Centre of Toronto by Numinus" and continue under Dr. Lewis' leadership.

Key Points: 
  • Founded in 2017 by Dr. Evan Lewis (MD), NCT will operate as the "Neurology Centre of Toronto by Numinus" and continue under Dr. Lewis' leadership.
  • Dr. Lewis will assume the role of VP, Psychedelic Neurology Services at Numinus.
  • The acquisition expands Numinus' presence into Ontario, in addition to an existing clinic and research facility in British Columbia, and clinics in Quebec.
  • These developments will form the basis for NCT by Numinus to expand into a clinical neurology centre with specialization in psychedelic neurology.